Samuel Finlayson

Samuel Finlayson, MD, PhD is a physician-scientist with expertise in artificial intelligence and rare pediatric disease. As SVP of Medical AI at OpenEvidence, he leads several efforts in AI product development, clinical data science, and collaborations with non-profit organizations to co-create content using AI and human expertise. He is also co-founder and Chief Scientific Officer of Team Hydro, a non-profit focused on hydrocephalus research. He serves as an Associate Editor at NEJM AI and a member of the AI Review Board at Seattle Children’s Hospital.

Samuel trained in pediatrics and medical genetics at Seattle Children’s Hospital and the University of Washington, where he will join the faculty as a Clinical Associate Professor in Summer 2026. Previously, he completed his undergraduate and master’s degrees at Stanford and his MD and PhD at Harvard and MIT under the guidance of Isaac Kohane (HMS DBMI) and Peter Szolovits (MIT CSAIL). His research spans a broad range of topics in biomedical artificial intelligence, from technology development to safety and governance, with a special interest in applications relevant to therapeutic development for rare diseases.